BNTC — Benitec Biopharma Share Price
0.000.00%
Last trade - 00:00- $18.12m
- -$2.25m
- $0.08m
- 21
- 12
- 100
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.17 | ||
| Price to Tang. Book | 1.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 297.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -138.99% | ||
| Return on Equity | -178.3% | ||
| Operating Margin | -35560.66% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 11.87 | 0.1 | 0.06 | 0.07 | 0.07 | 0.1 | 0.75 | -53.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 22nd, 2019
- Public Since
- July 11th, 2012
- No. of Shareholders
- 3,318
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,592,434
- Address
- 3940 Trust Way, HAYWARD, 94545
- Web
- https://benitec.com/
- Phone
- +1 5107800819
- Contact
- Irina Koffler
- Auditors
- BAKER TILLY US LLP
Upcoming Events for BNTC
Q4 2024 Benitec Biopharma Inc Earnings Release
Similar to BNTC
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Benitec Biopharma share price?
As of Today at 19:03 UTC, shares in Benitec Biopharma are trading at $6.99. This share price information is delayed by 15 minutes.
How has the Benitec Biopharma share price performed this year?
Shares in Benitec Biopharma last closed at $6.99 and the price had moved by +68.51% over the past 365 days. In terms of relative price strength the Benitec Biopharma share price has outperformed the S&P500 Index by +40.23% over the past year.
What are the analyst and broker recommendations for Benitec Biopharma?
The overall consensus recommendation for Benitec Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Benitec Biopharma dividend yield?
Benitec Biopharma does not currently pay a dividend.
Does Benitec Biopharma pay a dividend?
Benitec Biopharma does not currently pay a dividend.
When does Benitec Biopharma next pay dividends?
Benitec Biopharma does not currently pay a dividend.
How do I buy Benitec Biopharma shares?
To buy shares in Benitec Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Benitec Biopharma?
As of the previous close price of $6.99, shares in Benitec Biopharma had a market capitalisation of $18.12m.
Where are Benitec Biopharma shares listed?
Here are the trading details for Benitec Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BNTC
What kind of share is Benitec Biopharma?
Based on an overall assessment of its quality, value and momentum Benitec Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Benitec Biopharma share price forecast for 2024?
The analyst consensus target price for shares in Benitec Biopharma is $10.00. That is 42.99% above the last closing price of $6.99.
Analysts covering Benitec Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$2.95 for the next financial year.
What is the trend in the Benitec Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Benitec Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +87.79%.
As of the last closing price of $6.99, shares in Benitec Biopharma were trading +94.98% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Benitec Biopharma PE Ratio?
The Benitec Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Benitec Biopharma?
We do not have data on Benitec Biopharma's directors